In one paragraphArticle in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed, 12 citations in OpenAlex.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
13 authors at 5 institutions in 1 country.
Clayton J OtterDepartment of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID 0000-0003-1609-8105 Nicole BracciDepartment of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID 0000-0002-7298-4796 Nicholas A ParentiDepartment of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID 0000-0003-3673-1027 Li Hui TanDepartment of Otorhinolaryngology-Head and Neck Surgery, Division of Rhinology, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA.
Abhishek AsthanaDepartment of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.ORCID 0000-0002-5429-6199 Nathaniel JacksonTexas Biomedical Research Institute, San Antonio, TX, USA.
Robert H SilvermanDepartment of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.ORCID 0000-0003-2432-992X Noam A CohenDepartment of Otorhinolaryngology-Head and Neck Surgery, Division of Rhinology, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA.
Susan R WeissDepartment of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID 0000-0002-8155-4528 University of Pennsylvania · USTexas Biomedical Research Institute · USCleveland Clinic Lerner College of Medicine · USUniversity of Kansas · USPhiladelphia VA Medical Center · US
Funding
Synthetic Chemical Biology CoreP20GM113117 · NIGMS · UNIVERSITY OF KANSAS LAWRENCE · PI HEFTY, P SCOTT · 2016 to 2025
$23.9MUniversity of Pennsylvania Postdoctoral Opportunities in Research and TeachingK12GM081259 · NIGMS · UNIVERSITY OF PENNSYLVANIA · PI Janis K. Burkhardt · 2007 to 2026
$20.1MControl of Viral Pathogenesis by Regulation of 2-5A LevelsR01AI104887 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI SILVERMAN, ROBERT H., WEISS, SUSAN R · 2013 to 2023
$7.6MTRAINING IN VIROLOGYT32AI007324 · NIAID · WISTAR INSTITUTE · PI Paul Bates, Matthew D. Weitzman · 1989 to 2026
$6.8MMERS coronavirus: antagonism of double-stranded RNA induced host response by accessory proteinsR01AI140442 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI Susan R Weiss · 2018 to 2026
$5.1MTraining in Emerging Infectious DiseasesT32AI055400 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI CHERRY, SARA, HENSLEY, SCOTT ERIC · 2003 to 2022
$4.4MHuman coronavirus infection of the nasal epitheliumR01AI169537 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI Noam A Cohen, Susan R Weiss · 2022 to 2026
$3.7MDetermining mechanisms of innate immune modulation by ADP-ribosylationR35GM138029 · NIGMS · UNIVERSITY OF KANSAS LAWRENCE · PI Anthony R Fehr · 2020 to 2026
$2.7MThe origin and future protective activity of SARS-CoV-2 RBD specific neutralizing antibodiesR01AI161175 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI KOBIE, JAMES J, MARTINEZ-SOBRIDO, LUIS · 2021 to 2024
$2.5MAntiviral innate immune responses to pathogenic coronaviruses in the nasal epitheliumF30AI172101 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI OTTER, CLAYTON · 2023 to 2024
$68kCOVID-19: Elucidating the Role of the NasalEpithelium in SARS-CoV-2 Infection, Transmission, and PreventionI01BX005432 · VA · PHILADELPHIA VA MEDICAL CENTER · PI COHEN, NOAM A · 2021 to 2023
–BLRD VA I01 BX005432NIAID NIH HHS F30 AI172101NIAID NIH HHS R01 AI104887NIAID NIH HHS R01 AI140442NIAID NIH HHS R01 AI161175NIAID NIH HHS R01 AI169537NIAID NIH HHS T32 AI007324NIAID NIH HHS T32 AI055400NIGMS NIH HHS K12 GM081259NIGMS NIH HHS P20 GM113117NIGMS NIH HHS R35 GM138029
6 · The paper itselfAbstract
Severe acute respiratory syndrome coronavirus (SARS-CoV)-2 has caused millions of deaths since emerging in 2019. Innate immune antagonism by lethal CoVs such as SARS-CoV-2 is crucial for optimal replication and pathogenesis. The conserved nonstructural protein 15 (nsp15) endoribonuclease (EndoU) limits activation of double-stranded (ds)RNA-induced pathways, including interferon (IFN) signaling, protein kinase R (PKR), and oligoadenylate synthetase/ribonuclease L (OAS/RNase L) during diverse CoV infections including murine coronavirus and Middle East respiratory syndrome (MERS)-CoV. To determine how nsp15 functions during SARS-CoV-2 infection, we constructed a mutant recombinant SARS-CoV-2 (nsp15
Indexed as
dsRNA-induced pathwaysendoribonucleaseinterferonnsp15SARS-CoV-2
Identifiers
PMID38014074
PMCPMC10680701
OpenAlexW4388712065
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390